|
|
|
|
|
|
|
|
Conclusions: Combined bevacizumab and metronomic oral cyclophosphamide is a safe and effective regimen for heavily pre-treated ovarian cancer patients. Further research is needed on predictive factors to screen for those patients who will benefit from anti-angiogenic therapy.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.